September 1, 2020 -- Gilead Sciences has exclusively licensed the JTX-1811 novel cancer immunotherapy program from Jounce Therapeutics.
JTX-1811 is a monoclonal antibody designed to selectively deplete immunosuppressive tumor-infiltrating T regulatory (TITR) cells. JTX-1811 targets CCR8, a chemokine receptor enriched on TITR cells for depletion by an antibody-dependent cellular cytotoxicity mechanism. The program is on track to file an investigational new drug (IND) application in the first half of 2021.
Under the agreement, Gilead will make an $85 million upfront payment to, and a $35 million equity investment at a premium in, Jounce. Jounce may receive up to an additional $685 million in future clinical, regulatory, and commercial milestone payments. Jounce will also be eligible to receive royalties based on worldwide sales.
Jounce will lead development of JTX-1811 through IND clearance, at which point Gilead will have the sole right to develop JTX-1811.
The transaction is set to close in the second half of 2020.
Copyright © 2020 scienceboard.net